This program is supported by an independent educational grant from Pfizer. This education program is only available to healthcare professionals globally.

Join prostate cancer experts Dr. Michael Schweizer and Dr. Emmanuel Antonarakis for this accredited, interactive teaching session focused on the latest updates for 2026 in overcoming treatment resistance and optimizing therapeutic pathways in metastatic castration-resistant prostate cancer (mCRPC). Through real-world cases and expert-led discussion, faculty will translate emerging evidence into practical strategies to support sequencing decisions after AR pathway inhibitor (ARPI) progression.

Accreditation: 1 AMA PRA Category 1 Credits™

Session Overview

Overcoming Resistance and Optimizing Pathways

This case-based session explores how evolving insights into resistance biology can inform more precise, personalized treatment decisions in mCRPC. Faculty will guide learners through common clinical scenarios encountered after ARPI progression, highlighting how biomarkers, emerging mechanisms, and novel non-chemotherapy approaches may shape next steps in care.

• Review emerging insights into resistance biology beyond DNA repair, including lineage plasticity, AR co-activation, and epigenetic dysregulation, and how these concepts are influencing contemporary mCRPC thinking
• Discuss the growing translational rationale for targeting epigenetic pathways such as EZH2, including current evidence gaps and implications for future practice
• Compare novel non-chemotherapy approaches—including radioligand therapies, antibody–drug conjugates, and immunotherapies—and where these modalities may fit within emerging treatment paradigms
• Engage in expert-led Q&A, interactive polling, and a patient voice vignette highlighting real-world decision points, uncertainty, and practice variation

Who Should Attend?

This program is designed for healthcare professionals globally involved in the diagnosis, treatment selection, and ongoing management of patients with mCRPC, including:

• Medical and radiation oncologists
• Urologists
• Oncology nurses and nurse practitioners
• Physician assistants
• Pharmacists
• Others involved in prostate cancer care

Faculty

Michael Schweizer, M.D.

Medical oncologist specializing in genitourinary cancers with expertise in advanced prostate cancer, resistance mechanisms, and clinical trials evaluating novel therapeutic strategies in mCRPC.

Emmanuel Antonarakis, M.D.

Internationally recognized prostate cancer expert and clinician-scientist with extensive experience in resistance biology, biomarker-driven treatment selection, and translational research guiding precision approaches in mCRPC.

Faculty Disclosure Statement / Conflict of Interest

AffinityCE adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to AffinityCE any financial relationship with an ineligible organisation. AffinityCE has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant financial relationships are listed below. All individuals not listed have no relevant financial relationships.

Accreditation

Physicians

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 1 _AMA PRA Category 1 Credits_™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physician assistants should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioners

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and MedAll. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.

AffinityCE designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.

Nurses & Other Professionals

All other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity.

Requirements for Completion

In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.

System Requirements

Mobile device (e.g., large-format smart phone; laptop or tablet computer) or desktop computer with a video display of at least 1024 × 768 pixels at 24-bit color depth, capable of connecting to the Internet at broadband or faster speeds, with a current version Internet browser and popular document viewing software (e.g., Microsoft Office, PDF viewer, image viewer) installed. Support for streaming or downloadable audio-visual materials (e.g., streaming MP4, MP3 audio) in hardware and software may be required to view, review, or participate in portions of the program.

Unapproved and/or off-label use disclosure

AffinityCE/MedAll requires CE faculty to disclose to the participants:

1. When products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not US Food and Drug Administration [FDA] approved); and

2. Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion.

Disclaimer

This activity is intended for educational purposes only and does not establish a standard of care or replace clinical judgment. Any therapeutic or diagnostic strategies discussed must be evaluated in the context of each patient’s clinical circumstances, risks, and current evidence.

Learners should consult authoritative clinical guidelines and approved product information when considering treatment decisions.

All materials are used with permission. The views expressed are those of the faculty and do not necessarily reflect those of the accredited providers, MedAll, or any supporters.

Content is accurate as of the date of release.

Launch and Expiration Date: 23 February 2026 – 23 February 2026

Estimated time to complete this activity: 60 minutes